Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II study of nivolumab versus carboplatin + pemetrexed in EGFR-mutated non-squamous non-small cell lung cancer after EGFR-TKI resistance
jRCTs051180133Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jun 2016
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Nivolumab with Carboplatin + pemetrexed (2 arms). Primary endpoint: Progression-free survival. Started Jun 2016; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs051180133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180133.